Presbyopia Clinical Trial
Official title:
Dispensing Study to Assess Visual Performance of Prototype Contact Lenses
Verified date | June 2015 |
Source | Brien Holden Vision |
Contact | n/a |
Is FDA regulated | No |
Health authority | Australia: Human Research Ethics Committee |
Study type | Interventional |
The aim of this study is to assess visual performance of prototype soft contact lens designs compared to commercially available contact lenses over one-week of lens wear.
Status | Completed |
Enrollment | 67 |
Est. completion date | June 2015 |
Est. primary completion date | June 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Both |
Age group | 18 Years to 70 Years |
Eligibility |
Inclusion Criteria: - Able to read and comprehend English and give informed consent as demonstrated by signing a record of informed consent - Be at least 18 years old, male or female - Willing to comply with the wearing and clinical trial visit schedule as directed by the Investigator - Have ocular health findings considered to be "normal" and which would not prevent the participant from safely wearing contact lenses - Correctable to at least 6/12 (20/40) or better in each eye with contact lenses - Be willing to not wear contact lenses for a minimum of 2 days before each stage of the clinical trial (after informed consent) Exclusion Criteria: - Any pre-existing ocular irritation, injury or condition (including infection or disease) of the cornea, conjunctiva or eyelids that would preclude contact lens fitting and safe wearing of contact lenses - Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus. Conditions such as systemic hypertension and arthritis do not automatically exclude prospective participants - Use of or a need for concurrent category S3 and above ocular medication at enrolment and/or during the clinical trial - Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology or contact lens performance either in an adverse or beneficial manner at enrolment and/or during the clinical trial NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used - Eye surgery within 12 weeks immediately prior to enrolment for this trial. - Previous corneal refractive surgery - Contraindications to contact lens wear - Known allergy or intolerance to ingredients in any of the clinical trial products The Investigator may, at his/her discretion, exclude anyone who they believe may not be able to fulfil the clinical trial requirements or it is believed to be in the participant's best interests |
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Australia | Brien Holden Vision Institue, Clinical Research Trials Center | Sydney | New South Wales |
Lead Sponsor | Collaborator |
---|---|
Brien Holden Vision |
Australia,
Stapleton F, Keay L, Edwards K, Naduvilath T, Dart JK, Brian G, Holden BA. The incidence of contact lens-related microbial keratitis in Australia. Ophthalmology. 2008 Oct;115(10):1655-62. doi: 10.1016/j.ophtha.2008.04.002. Epub 2008 Jun 5. — View Citation
Young G, Veys J, Pritchard N, Coleman S. A multi-centre study of lapsed contact lens wearers. Ophthalmic Physiol Opt. 2002 Nov;22(6):516-27. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in visual performance over 1-week lens wear | Visual Acuity Visual acuity will be recorded on an interval scale. Data will be summarised as means ± standard deviations. No transformation is likely to be required. Visual acuity will be compared between test and control lens types and time across 1 week. Interactions will be tested and, if present, the significance of lens types will be determined at each time point and over time for each lens type. Visual acuity will be analysed using linear mixed model with subject random intercepts and / or paired t-test. | after about 20 minutes of lens wear and after about 1 week of lens wear | No |
Secondary | Change in subjective response over 1-week of lens wear | Subjective ratings Questionnaire Subjective ratings will be recorded on a scale of 1 to 10 on steps of 1. Data will be summarised as means ± standard deviations. No transformation is likely to be required. Subjective ratings will be compared between test and control lens types and time across 1 week. Interactions will be tested and, if present, the significance of lens type will be determined at each time point and over time for each lens type. Subjective ratings will be analysed using linear mixed model with subject random intercepts and / or paired t-test. | After about 40 mins of lens wear and after 2 days, 4 days and 1 week of lens wear | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05326607 -
Pilot Clinical Investigation of Adaptative Eyeglasses for the Correction of Presbyopia
|
N/A | |
Recruiting |
NCT06060041 -
IC-8 Apthera IOL New Enrollment Post Approval Study
|
||
Completed |
NCT05495971 -
Extended Depth of Focus Contact Lenses for Presbyopia
|
N/A | |
Completed |
NCT05464732 -
Vivity IOL: Emmetropia Compared to Monovision.
|
N/A | |
Recruiting |
NCT06045299 -
Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia
|
Phase 3 | |
Active, not recruiting |
NCT04151550 -
Safety & Efficacy of the Laser Scleral Microporation Procedure (Philippines)
|
N/A | |
Not yet recruiting |
NCT05506553 -
Comparison of Aspheric Toric Intraocular Lenses for Micro-monovision
|
N/A | |
Completed |
NCT02554396 -
Evaluation of the Efficacy and Safety of PRX-100 in the Treatment of Early to Moderate Presbyopia
|
Phase 2 | |
Completed |
NCT02235831 -
DAILIES® AquaComfort Plus® Multifocal (MF) - Comparative Assessment of Visual Performance
|
N/A | |
Enrolling by invitation |
NCT01443585 -
Clinical Evaluation of a Progressive Addition Lens (PAL)
|
N/A | |
Completed |
NCT01591499 -
Clinical Evaluation of Biofinity Multifocal Compared With Air Optix Aqua Multifocal and With PureVision Multifocal
|
N/A | |
Completed |
NCT04983589 -
A Study to Assess Safety and Efficacy in Participants Age 40 to 55 With Presbyopia (Old Eye) Who Receive AGN-190584 in Both Eyes Twice Daily
|
Phase 3 | |
Completed |
NCT02740010 -
The Visual Performances of a Progressive Multifocal Intraocular Lens With Extended Depth of Focus
|
||
Recruiting |
NCT05796453 -
Post Market Clinical Follow-up (PMCF) Study of Clareon Vivity & Clareon PanOptix
|
N/A | |
Completed |
NCT02516306 -
A Study to Evaluate the Safety and Efficacy of EV06 Ophthalmic Solution in Improving Vision in Subjects With Presbyopia
|
Phase 1/Phase 2 | |
Completed |
NCT05359380 -
The Impact of Light Conditions on the Efficacy of Multifocal Intraocular Lens Implantation in Activities of Daily Living
|
||
Not yet recruiting |
NCT04522427 -
Study of Presbyopia-correcting Intraocular Lenses in Eyes With Previous Corneal Refractive Surgery
|
N/A | |
Completed |
NCT03688425 -
Comparison of Clinical Outcomes POD L GF vs POD F GF in Asian Eyes
|
N/A | |
Recruiting |
NCT06053463 -
Evaluation of Soft Multifocal Lenses in Presbyopic Previous Contact Lens Wearers
|
N/A | |
Completed |
NCT05069415 -
Monofocal IOL Visual Outcomes When Targeting Mini Monovision
|
N/A |